Skip to main content

Adoxa CK Side Effects

Generic name: doxycycline

Medically reviewed by Drugs.com. Last updated on Aug 25, 2023.

Note: This document contains side effect information about doxycycline. Some dosage forms listed on this page may not apply to the brand name Adoxa CK.

Applies to doxycycline: oral capsule, oral capsule extended release, oral powder for suspension, oral syrup, oral tablet, oral tablet delayed release.

Serious side effects of Adoxa CK

Along with its needed effects, doxycycline (the active ingredient contained in Adoxa CK) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking doxycycline:

Less common

Incidence not known

Other side effects of Adoxa CK

Some side effects of doxycycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to doxycycline: injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral kit, oral powder for reconstitution, oral syrup, oral tablet, oral and topical kit.

Nervous system

Benign intracranial hypertension resulting in permanent loss of vision has been reported.

A 70-year-old female patient with no significant medical history suddenly developed a severe headache followed by vomiting about 15 minutes after the initial dose of this drug. The patient also experienced memory dysfunction; she could not remember the events of the afternoon prior to the dose of this drug and could not retain the information after she was reminded. The incident lasted about 30 minutes and she was transported to the hospital for further evaluation. No further cause, such as intoxication or trauma, could be elicited. Once at the hospital, the patient was able to remember the events of the afternoon and could retain new information, but amnesia regarding the events of the 30 minutes following the onset of the headache persisted. The patient's laboratory results, computerized tomography scan, MRI scan, cerebrospinal fluid, and electroencephalogram showed no pathology. When the patient was discharged 2 days later, the amnesia for the 30 minutes continued. After elimination of other symptomatic causes, the amnesia was concluded to be due to this drug because of the close relation of the dose and the onset of symptoms.[Ref]

Very common (10% or more): Headache (up to 26%)

Common (1% to 10%): Sinus headache

Rare (0.01% to 0.1%): Bulging fontanels (in infants), benign intracranial hypertension (pseudotumor cerebri [symptoms include blurred vision, scotomata, diplopia]), tinnitus

Frequency not reported: Hypoesthesia, increased intracranial pressure, paresthesia, somnolence, stupor, taste loss, drowsiness, amnesia, paresthesias of body areas exposed to sunlight, phrenic nerve paralysis after sclerotherapy

Postmarketing reports: Pseudotumor cerebri, headache, dizziness[Ref]

Other

Very common (10% or more): Common cold (up to 22%), influenza symptoms (up to 11%)

Common (1% to 10%): Injury/accidental injury, pain, infection, fungal infection, influenza

Rare (0.01% to 0.1%): Candida infection/candidiasis, flushing, retrosternal pain

Frequency not reported: Malaise, overgrowth of nonsusceptible organisms (superinfection)

Postmarketing reports: Asthenia[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 13.4%)

Common (1% to 10%): Nausea/vomiting, toothache, tooth disorder, dyspepsia, diarrhea, periodontal abscess, acid indigestion, upper abdominal pain, abdominal distention, abdominal pain, stomach discomfort, dry mouth

Uncommon (0.1% to 1%): Gum pain, heartburn/gastritis

Rare (less than 0.1%): Glossitis, dysphagia, enterocolitis, inflammatory lesions (with candidal/monilial overgrowth) in the anogenital region, esophagitis, esophageal ulcerations, pancreatitis, pseudomembranous colitis, Clostridium difficile colitis, stomatitis

Frequency not reported: Clostridium difficile-associated diarrhea, esophageal irritation, ulceration, epigastric burning, black hairy tongue, tooth discoloration/adult tooth staining, vomiting, enamel hypoplasia, staphylococcal enterocolitis

Postmarketing reports: Bloody diarrhea, colitis, constipation, superficial tooth discoloration[Ref]

Numerous cases of esophageal ulceration have been reported. In most cases, the patients had taken their medication at bedtime, usually without enough liquid. Patients often presented with severe retrosternal pain and difficulty swallowing. Ulcerations generally resolved within a week after discontinuing the drug. In 1 case report, severe hiccups of 4-day duration associated with esophagitis followed the first dose of this drug.

Esophagitis and esophageal ulcerations have been reported in patients taking the capsule or tablet formulations of tetracycline-class antibiotics. Most of these patients took the drug immediately before going to bed.[Ref]

Musculoskeletal

Common (1% to 10%): Joint pain/arthralgia, back pain/back ache

Uncommon (0.1% to 1%): Muscle pain/myalgia[Ref]

Respiratory

Common (1% to 10%): Nasopharyngitis, sore throat, sinus congestion, coughing, sinusitis, bronchitis, nasal congestion, pharyngolaryngeal pain

Frequency not reported: Bronchospasm

Dermatologic

In a double-blinded study, this drug was found to be more phototoxic than minocycline and demeclocycline. Paresthesias of the body areas exposed to sunlight may be early signs of sunburn reactions.

A case report of a possible photoallergic reaction described scaly erythema and vesicles on the face and neck associated with administration of this drug. Upon rechallenge, a flare with erythema, itching, and burning occurred in the same area.

Another case report was documented in Australian troops treated with 100 mg daily for malaria prophylaxis while on deployment in East Timor, a group of islands within the Malaysian archipelago located close to the equator. Of the 135 troops, 22 exhibited phototoxic reactions to low doses of this drug that resembled severe sunburn with erythematous plaques on the sun-exposed areas. The troops used a sunscreen containing oxybenzone.

An 11-year-old boy treated with this drug for brucellosis was evaluated for painless brown nail discoloration. This drug was initiated for brucellosis but stopped when the boy developed photosensitivity, but 15 days after the initiation of therapy brown nail discoloration developed. Other than the brown discoloration, the boy's physical condition was normal and the discoloration disappeared within 1 month.[Ref]

Common (1% to 10%): Rash (including maculopapular rash, erythematous rash), photosensitivity reaction/dermatitis

Rare (0.01% to 0.1%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, photoonycholysis, drug reaction with eosinophilia and systemic symptoms (DRESS)

Frequency not reported: Nail discoloration, phototoxicity, photoallergic reaction, morbilliform rash, onycholysis, pustular rash

Postmarketing reports: Pruritus, urticaria

Tetracyclines:

-Frequency not reported: Hyperpigmentation[Ref]

Genitourinary

Common (1% to 10%): Menstrual cramps, bacterial vaginitis, vulvovaginal mycotic infection

Uncommon (0.1% to 1%): Vaginal infection

Frequency not reported: Vaginal itch, vaginitis

Postmarketing reports: Vaginal candidiasis/moniliasis, anogenital moniliasis[Ref]

Cardiovascular

Common (1% to 10%): Hypertension, increased blood pressure

Frequency not reported: Phlebitis (with IV administration)

Hepatic

Common (1% to 10%): Increased AST

Rare (0.01% to 0.1%): Abnormal hepatic function, hepatic failure, hepatitis, hepatotoxicity, jaundice

Frequency not reported: Acute hepatocellular injury, cholestatic reactions, cholestatic hepatitis, fatty liver degeneration, transient increases in liver function tests[Ref]

Metabolic

Common (1% to 10%): Increased blood LDH, increased blood glucose

Rare (0.01% to 0.1%): Decreased appetite, porphyria

Frequency not reported: Hypoglycemia, anorexia[Ref]

Hypoglycemia in a nondiabetic patient has been reported.[Ref]

Psychiatric

Common (1% to 10%): Anxiety

Frequency not reported: Confusion, depression, hallucination

Hypersensitivity

Common (1% to 10%): Anaphylactic reaction (including angioedema, exacerbation of systemic lupus erythematosus, pericarditis, hypersensitivity, serum sickness, Henoch-Schonlein purpura, hypotension, dyspnea, tachycardia, peripheral edema, urticaria)

Frequency not reported: Hypersensitivity reactions (including urticaria, angioneurotic edema, anaphylactic shock, anaphylaxis, anaphylactoid reactions, anaphylactoid purpura, serum sickness, hypotension, pericarditis, exacerbation of systemic lupus erythematosus, dyspnea, peripheral edema, tachycardia)

Postmarketing reports: Mild allergic reactions[Ref]

Hematologic

Rare (0.01% to 0.1%): Hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia

Frequency not reported: Increased prothrombin time, leukopenia, thrombocytopenic purpura[Ref]

Renal

Rare (0.01% to 0.1%): Increased BUN/blood urea (dose-related)

Frequency not reported: Acute renal failure[Ref]

Endocrine

Rare (0.01% to 0.1%): Microscopic brown-black discoloration of the thyroid gland[Ref]

The long-term use of tetracyclines has been associated with microscopic brown-black discoloration of the thyroid gland; abnormal thyroid function has not been reported.[Ref]

Ocular

Frequency not reported: Diplopia, papilledema, loss of vision (associated with drug-induced benign intracranial hypertension), conjunctivitis, periorbital edema[Ref]

Immunologic

Tetracyclines:

-Frequency not reported: Autoimmune syndromes

Frequently asked questions

References

1. Kirse DJ, Suen JY, Stern SJ (1997) "Phrenic nerve paralysis after doxycycline sclerotherapy for chylous fistula." Otolaryngol Head Neck Surg, 116, p. 680-3

2. Digre KB (2003) "Not so benign intracranial hypertension." BMJ, 326, p. 613-4

3. Friedman DI, Gordon LK, Egan RA, et al. (2004) "Doxycycline and intracranial hypertension." Neurology, 62, p. 2297-9

4. (2005) "Product Information. Adoxa (doxycycline)." Doak Dermatologics Division

5. Cerner Multum, Inc. "UK Summary of Product Characteristics."

6. Hasin T, Davidovitch N, Cohen R, et al. (2006) "Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med, 355, p. 148-55

7. Heveling T, Kubalek R (2006) "Doxycycline-induced amnesia : a case report." Eur J Clin Pharmacol, 63, p. 95-6

8. Del Rosso JQ, Webster GF, Jackson M, et al. (2007) "Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea." J Am Acad Dermatol, 56, p. 791-802

9. Tabibian JH, Gutierrez MA (2009) "Doxycycline-induced pseudotumor cerebri." South Med J, 102, p. 310-1

10. (2014) "Product Information. Acticlate (doxycycline)." Aqua Pharmaceuticals LLC

11. (2002) "Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals

12. (2001) "Product Information. Periostat (doxycycline)." Collagenex Pharmaceuticals

13. Story MJ, McCloud PI, Boehm G (1991) "Doxycycline tolerance study: incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs vibramycin')." Eur J Clin Pharmacol, 40, p. 419-21

14. Aarons B, Bruns BJ (1980) "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J, 91, p. 27

15. Geschwind A (1984) "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust, 140, p. 223

16. Amendola MA, Spera TD (1985) "Doxycycline-induced esophagitis." JAMA, 253, p. 1009-11

17. Foster JA, Sylvia LM (1994) "Doxycyline-induced esophageal ulceration." Ann Pharmacother, 28, p. 1185-7

18. Adverse Drug Reactions Advisory Committee (1994) "Doxycycline-induced oesophageal ulceration." Med J Aust, 161, p. 490

19. Golledge CL, Riley TV (1995) "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet, 345, p. 1377-8

20. Tzianetas I, Habal F, Keystone JS (1996) "Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria." Am J Trop Med Hyg, 54, p. 203-4

21. Smith K, Leyden JJ (2005) "Safety of doxycycline and minocycline: a systematic review." Clin Ther, 27, p. 1329-42

22. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA (2006) "Efficacy of Gentamicin plus Doxycycline versus Streptomycin plus Doxycycline in the Treatment of Brucellosis in Humans." Clin Infect Dis, 42, p. 1075-80

23. (2006) "Product Information. Oracea (doxycycline)." Collagenex Pharmaceuticals

24. Wormser GP (2006) "Clinical practice. Early Lyme disease." N Engl J Med, 354, p. 2794-801

25. Nelson R, Parker SR (2006) "Doxycycline-induced staining of adult teeth: the first reported case." Arch Dermatol, 142, p. 1081-2

26. Croft AM, Jackson CJ, Darbyshire AH (2006) "Doxycycline for the prevention of tick-borne relapsing fever." N Engl J Med, 355, 1614; author reply 1614-5

27. Grochenig HP, Tilg H, Vogetseder W (2006) "Clinical challenges and images in GI. Pill esophagitis." Gastroenterology, 131, 996, 1365

28. (2007) "Low-Dose Doxycycline (Oracea) for Rosacea." Med Lett Drugs Ther, 49, p. 5-6

29. Ramsakal A, Mangat L (2007) "Images in clinical medicine. Lingua villosa nigra." N Engl J Med, 357, p. 2388

30. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK (2008) "Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial." Int J Dermatol, 47, p. 284-8

31. Freedman DO (2008) "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med, 359, p. 603-12

32. de Vries HJ, Smelov V, Middelburg JG, Pleijster J, Speksnijder AG, Morre SA (2009) "Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment." Clin Infect Dis, 48, e53-6

33. Curley RK, Verbov JL (1987) "Stevens-Johnson syndrome due to tetracyclines: a case report (doxycycline) and review of the literature." Clin Exp Dermatol, 12, p. 124-5

34. Lewis-Jones MS, Evans S, Thompson CM (1988) "Erythema multiforme occurring in association with lupus erythematosus during therapy with doxycycline." Clin Exp Dermatol, 13, p. 245-7

35. Frost P, Weinstein GD, Gomez EC (1972) "Phototoxic potential of minocycline and doxycycline." Arch Dermatol, 105, p. 681-3

36. Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A (1997) "Photosensitivity due to doxycycline hydrochloride with an unusual flare." Contact Dermatitis, 37, p. 93-4

37. Lim DS, Murphy GM (2003) "High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor." Br J Dermatol, 149, p. 213-4

38. Passier A, Smits-van Herwaarden A, van Puijenbroek E (2004) "Photo-onycholysis associated with the use of doxycycline." BMJ, 329, p. 265

39. Akcam M, Artan R, Akcam FZ, Yilmaz A (2005) "Nail discoloration induced by doxycycline." Pediatr Infect Dis J, 24, p. 845-846

40. Habif TP (2006) "Images in clinical medicine. Doxycycline-induced phototoxicity." N Engl J Med, 355, p. 182

41. Bjornsson E, Lindberg J, Olsson R (1997) "Liver reactions to oral low-dose tetracyclines." Scand J Gastroenterol, 32, p. 390-5

42. Basaria S, Braga M, Moore WT (2002) "Doxycycline-induced hypoglycemia in a nondiabetic young man." South Med J, 95, p. 1353-4

43. Raeder JC (1984) "Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment." Drug Intell Clin Pharm, 18, p. 481-2

44. Lochhead J, Elston JS (2003) "Doxycycline induced intracranial hypertension." BMJ, 326, p. 641-2

45. Chan AY, Liu DT, Friedman DI, Gordon LK, Egan RA (2005) "Doxycycline and intracranial hypertension." Neurology, 64, p. 765-6

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.